Io­vance's TIL ther­a­py makes ear­ly head­way in lung can­cer; An­tios and Ar­bu­tus join hands on HBV com­bo treat­ment

Io­vance has post­ed a first look at its tu­mor in­fil­trat­ing lym­pho­cytes as a treat­ment for non-small cell lung can­cer, paving the way for a piv­otal study.

Among 28 pa­tients en­rolled in Co­hort 3B of the IOV-COM-202 bas­ket study — 24 of whom were evalu­able — in­ves­ti­ga­tors record­ed an over­all re­sponse rate of 21.4% at the in­ter­im, with 1 com­plete re­sponse and 5 par­tial re­spons­es. All pa­tients in the group had pro­gressed on pri­or im­mune check­point in­hibitor ther­a­py, and some had re­ceived ty­ro­sine ki­nase in­hibitors. The six re­spon­ders al­so un­der­went chemother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.